MannKind Announces Settlement of Convertible Senior Notes MannKind (Nasdaq: MNKD) announced settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all tendered for conversion prior to the March 1, 2026 maturity.The company settled on March 4, 2026 using $35.5 million in cash and issuance of 569,023 shares of common stock.

#MNKD MannKind Announces Settlement of Convertible Senior Notes

www.stocktitan.net/news/MNKD/mann-kind-anno...

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update MannKind (Nasdaq: MNKD) reported Q4 2025 revenue of $112M, up 46% year-over-year, and full year 2025 revenue of $349M, up 22% vs. 2024. Furoscix and Afrezza each generated about $23M in Q4 2025.The company completed the scPharma acquisition, holds $176M in cash and investments, and flagged two FDA PDUFA dates: Afrezza pediatric on May 29, 2026 and Furoscix ReadyFlow on July 26, 2026. Nintedanib DPI Phase 1b topline data expected in 2H 2026.

#MNKD MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/MNKD/mann-kind-repo...

MannKind Provides Business Updates and 2026 Growth Drivers MannKind (Nasdaq: MNKD) provided business updates and outlined 2026 growth drivers including commercial momentum, recent acquisition activity, and clinical progress.Key points: a record fourth quarter with net revenue >$100 million, acquisition of scPharmaceuticals, multiple FDA review acceptances with PDUFA dates (Afrezza label update Jan 23, 2026; Afrezza pediatric sBLA May 29, 2026; FUROSCIX ReadyFlow sNDA July 26, 2026), first patient enrolled in INFLO-1 (nintedanib DPI) in Dec 2025, and ongoing collaborations with United Therapeutics including a planned Tyvaso DPI bridging study.

#MNKD MannKind Provides Business Updates and 2026 Growth Drivers

www.stocktitan.net/news/MNKD/mann-kind-prov...

MannKind Shares FUROSCIX® Business Updates MannKind Corporation (Nasdaq: MNKD) today announced two business

#MNKD MannKind Shares FUROSCIX® Business Updates

www.stocktitan.net/news/MNKD/mann-kind-shar...

#MNKD MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

www.stocktitan.net/news/MNKD/mann-kind-prov...

#MNKD MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/MNKD/mann-kind-corp...

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025 MannKind (Nasdaq: MNKD) will release its third quarter 2025 financial results before the market opens on November 5, 2025. The company will host a webcast at 9:00 a.m. Eastern Time the same day to discuss results and provide a business update.Investors can access the live webcast and a replay via the company’s investor website at https://investors.mannkindcorp.com/events-and-presentations; the replay will be available within 24 hours and remain accessible for approximately 90 days.

#MNKD MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

www.stocktitan.net/news/MNKD/mann-kind-corp...

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care MannKind (Nasdaq: MNKD) completed its acquisition of scPharmaceuticals on October 7, 2025, creating a cardiometabolic-focused commercial platform. The deal consideration was $5.35 per share in cash plus one non-tradable contingent value right (CVR) for up to $1.00, for total consideration of up to $6.35 per share. MannKind cited an annualized revenue run rate of over $370 million based on Q2 2025 results, driven by Afrezza, FUROSCIX, V-Go and Tyvaso DPI–related revenues. The FUROSCIX ReadyFlow autoinjector supplemental NDA was filed in Q3 2025. Following a merger under Delaware law, scPharmaceuticals became a wholly owned subsidiary and its Nasdaq symbol SCPH ceased trading.

#MNKD MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

www.stocktitan.net/news/MNKD/mann-kind-comp...

Charts of the Day - small-cap stocks forming bearish harami candlestick signal, Mon Oct 6th - #ERAS #MNKD - More: crystalequityresearch.com/charts-of-th... - #smallcap

Most Searched, Tuesday September 2, 2025 – Crystal Equity Research

Most searched small-cap stocks, Tue Sept 2nd - #MNKD #RR #ONDS #SHFS #BBAI #NUKK #IQ #CIFR #UUU #WULF #WRD #VLRS #SBET #PTEN #OPEN #MGNX #LUNR #HWH #CAAS - More: crystalequityresearch.com/most-searche... - #smallcap

Leading Indicators, Tuesday September 2, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Tue Sept 2nd - #UUU #ITRG #GROY #CARV #ULCC #SHFS #MNKD #MLYS #CARM #TIXT #MUX - More: crystalequityresearch.com/leading-indi... - #smallcap

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy MannKind Corporation (NASDAQ: MNKD) has expanded its collaboration with United Therapeutics (NASDAQ: UTHR) to develop a second dry powder inhalation therapy. This follows their successful partnership that resulted in Tyvaso DPI, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.Under the expanded agreement, MannKind will utilize its Technosphere® platform to formulate a new investigational molecule, while United Therapeutics will handle preclinical and clinical development. The deal includes an upfront payment of $5 million to MannKind, potential development milestones up to $35 million, and 10% royalties on net sales of any resulting product.

#MNKD MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

www.stocktitan.net/news/MNKD/mann-kind-anno...

$10B Market Opportunity: MannKind Acquires FUROSCIX Maker scPharmaceuticals in Strategic Cardiorenal Expansion MannKind to pay $5.35/share plus $1 CVR for scPharmaceuticals, adding FUROSCIX heart failure treatment. Combined revenue run rate of $370M. Deal closes Q4 2025, backed by $175M Blackstone funding.

#MNKD MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

www.stocktitan.net/news/MNKD/mann-kind-to-a...

MannKind (MNKD) Q2 Revenue Rises 6% | The Motley Fool

#MNKD #eece2b98-b65f-48d9-8456-3b3348a3c041 #data-news

Origin | Interest | Match

MannKind Sets Critical Q2 2025 Earnings Call: Pre-Market Release Plus Key Business Updates Coming August 6 Get ready for MannKind's Q2 2025 results dropping before market open on Aug 6. Join the 9AM ET webcast for latest financial metrics and business insights. Save your spot.

#MNKD MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

www.stocktitan.net/news/MNKD/mann-kind-corp...

JUST IN: ( NASDAQ: #MNKD ) Objective long/short (MNKD) Report

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update MannKind Corporation (MNKD) reported strong Q1 2025 financial results with total revenues of $78.4M, up 18% year-over-year. The company achieved net income of $13.2M (up 24%) and non-GAAP net income of $21.6M (up 43%). Revenue growth was driven by increased Tyvaso DPI royalties and collaboration services. Afrezza showed strong performance with 20% NRx growth and 14% TRx growth. Key pipeline developments include plans to submit sBLA for Afrezza in pediatric patients mid-2025, progress in MNKD-101's Phase 3 trial for NTM lung disease with 55 patients randomized, and advancement of MNKD-201 program. The company maintained a strong financial position with $198M in cash and equivalents as of March 31, 2025.

#MNKD MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/MNKD/mann-kind-corp...

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 MannKind (MNKD) will present five studies on inhaled insulin at the 18th International Conference on Advanced Technologies and Treatments for Diabetes in Amsterdam, March 19-22, 2025. The presentations will showcase data from the INHALE-1 pediatric and INHALE-3 adult studies of Afrezza®.Key presentations include research on pulmonary inhaled insulin, pediatric applications, sustained benefits from the INHALE-3 extension study, post-prandial glucose excursion comparisons between youth and adults with Type 1 diabetes, and a comparison study of inhaled Technosphere insulin plus insulin degludec versus usual care in adults.The company anticipates filing a supplemental New Drug Application (sNDA) for Afrezza in the pediatric population in 2025. MannKind will also host booth #40 in the exhibit hall for scientific exchange with their Clinical Education Team.

#MNKD MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

www.stocktitan.net/news/MNKD/mann-kind-show...

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update MannKind (MNKD) reported strong financial results for Q4 and full year 2024. The company achieved annual revenues of $286M, up 43% from 2023, with Q4 revenues of $77M (+31% YoY). Net income for 2024 reached $28M, with Q4 contributing $7M.Key financial highlights include debt principal reduction of $236M, with remaining convertible debt of $36M, and year-end cash position of $203M. The company made significant clinical progress, including positive results from the INHALE-1 pediatric trial for Afrezza, advancement of MNKD-101 to Global Phase 3, and completion of MNKD-201 Phase 1.Commercial developments include Afrezza's approval in India with expected shipments in Q4 2025, and the appointment of Dominic Marasco as President of the Endocrine Business Unit. The company maintains a strong growth trajectory with an annual run rate of $300M by year-end.

#MNKD MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/MNKD/mann-kind-corp...

MannKind Sets Stage for 2024 Performance Review: CEO and CFO to Unveil Full Year Results Join CEO Michael Castagna and CFO Chris Prentiss for MannKind's comprehensive financial review and business outlook, starting 4:30 PM ET.

#MNKD MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

www.stocktitan.net/news/MNKD/mann-kind-corp...

MannKind Slashes Debt by 84% in Major Financial Restructuring, Converts $194M Notes to Equity MannKind transforms its balance sheet through strategic debt restructuring, reducing total debt to $36.3M while maintaining $180M+ cash position. Learn about this pivotal financial move.

#MNKD MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

www.stocktitan.net/news/MNKD/mann-kind-corp...

MannKind's Inhaled Insulin Shows Promise in Pivotal Pediatric Trial, Eyes FDA Submission MannKind's Afrezza meets key endpoint in Phase 3 pediatric study, demonstrating comparable efficacy to insulin injections with favorable safety profile in children 4-17 years old.

#MNKD MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

www.stocktitan.net/news/MNKD/mann-kind-anno...

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India MannKind (MNKD) announced that India's Central Drugs Standard Control Organisation (CDSCO) has approved Afrezza (insulin human) Inhalation Powder for adults. This approval follows existing approvals in the United States and Brazil. The company expects to ship the product to their partner Cipla by the end of 2025.This milestone is particularly significant as India has the second-highest burden of diabetes worldwide, with over 74 million people affected. The partnership between MannKind and Cipla, established in May 2018, involves Cipla handling regulatory approvals, marketing, and sales in India, while MannKind is responsible for product supply.According to the International Diabetes Federation, diabetes affects 537 million adults globally, with projections reaching 643 million by 2030 and 783 million by 2045.

#MNKD CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

#investing #stocks #StockMarket

www.stocktitan.net/news/MNKD/cdsco-approves...